Source: http://www.google.es/patents/US8974445
Timestamp: 2017-09-25 15:27:02
Document Index: 76855506

Matched Legal Cases: ['Application No. 61', 'Application No. 2006', 'Application No. 20060270975', 'Application No. 2004', 'Application No. 2002', 'art, 78', 'art, 86', 'Application No. 10', 'Application No. 10']

Patente US8974445 - Methods and apparatus for treatment of cardiac valve insufficiency - Google Patentes
Mitral valve insufficiency is treated by introducing an expansible device such as a balloon bearing an ultrasonic transducer into the heart so that the transducer is positioned adjacent the mitral annulus but spaced from the mitral annulus, and actuating the transducer to heat the mitral annulus, denature...http://www.google.es/patents/US8974445?utm_source=gb-gplus-sharePatente US8974445 - Methods and apparatus for treatment of cardiac valve insufficiency
Número de publicación US8974445 B2
Número de solicitud US 12/684,067
Fecha de prioridad 9 Ene 2009
También publicado como EP2376011A1, EP2376011A4, US20100179424, WO2010080886A1, WO2010080886A8
Número de publicación 12684067, 684067, US 8974445 B2, US 8974445B2, US-B2-8974445, US8974445 B2, US8974445B2
Inventores Reinhard Warnking, Eugene J. Jung, Yong Zou, Jacques Seguin, Mano Iyer
Cesionario original Recor Medical, Inc.
Citas de patentes (873), Otras citas (147), Citada por (10), Clasificaciones (17), Eventos legales (5)
Methods and apparatus for treatment of cardiac valve insufficiency
US 8974445 B2
Mitral valve insufficiency is treated by introducing an expansible device such as a balloon bearing an ultrasonic transducer into the heart so that the transducer is positioned adjacent the mitral annulus but spaced from the mitral annulus, and actuating the transducer to heat the mitral annulus, denature collagen in the annulus and thereby shrink the annulus.
1. An apparatus for ablating cardiac tissue while reducing disruption of natural blood flow through a cardiac valve of a mammalian subject, the apparatus comprising:
an elongated catheter having proximal and distal regions; and
an emitter unit including an ultrasonic transducer and an expandable balloon positioned along a distal portion of the elongated catheter, the expandable balloon comprising a proximal portion, a distal portion and a transition region therebetween, the transition region extending from a distal end of the proximal portion to a proximal end of the distal portion, wherein a diameter of the expandable balloon, when expanded, at the distal end of the proximal portion is larger than a diameter of the balloon at the proximal end of the distal portion, wherein the expandable balloon, when expanded, comprises an abrupt change in diameter along the transition region, the distal end of the proximal portion of the expandable balloon, when expanded, being angled relative to a proximal end of the transition region by an angle greater than zero degrees, wherein the distal portion of the expandable balloon, when expanded, tapers in the distal direction from the proximal end of the distal portion to a distal end of the distal portion, wherein the ultrasonic transducer extends axially at least partially over the transition region of the expandable balloon, wherein the expandable balloon surrounds the ultrasonic transducer, wherein the ultrasonic transducer is configured and arranged such that, in use, when ultrasonic energy is emitted, the emitted ultrasonic energy causes shrinkage of the annulus of the valve, wherein, in use, the expandable balloon is constructed and arranged to hold the transducer spaced apart from the annulus of the valve and to retain the leaflets of the valve out of a path of the ultrasonic energy when the expandable balloon is deployed in situ and expanded, and the ultrasonic transducer is generally aligned with the annulus of the valve;
wherein the apparatus is configured so that, when the emitter unit is positioned within the valve, (i) the leaflets of the valve contact an exterior of the expandable balloon and form a seal against the expandable balloon, and (ii) an outer diameter of the expandable balloon is less than a cross-sectional dimension of the annulus of the valve so that the expandable balloon does not completely occlude the annulus thereby permitting blood to uninterruptedly flow through the valve, between the leaflets and the exterior of the expandable balloon, wherein the distal portion of the expandable balloon comprises a smooth outer surface so as to reduce the likelihood of damage to the leaflets of the valve.
2. The apparatus of claim 1 wherein the catheter is configured, when in use, to position the emitter unit adjacent to a posterior aspect of the annulus.
3. The apparatus of claim 1, wherein the distal portion of the expandable balloon includes a smaller cross-sectional area than the proximal portion of the expandable balloon when the expandable balloon is in an expanded condition during use.
4. The apparatus of claim 1, wherein the distal portion of the expandable balloon comprises a curved outer profile from the transition region to the distal end of the distal portion.
5. The apparatus of claim 1, wherein there is a decrease in diameter at the transition region between the proximal and distal portions to facilitate aligning the ultrasonic transducer with the annulus of the valve.
This application claims the benefit of U.S. Provisional Patent Application No. 61/204,744, filed Jan. 9, 2009 and entitled “Treatment of Mitral Valve Insufficiency,” the entire contents of which are incorporated by reference herein.
The present invention relates to treatment of cardiac valves in a mammalian subject.
Humans and other mammals have a four-chambered heart. Blood from the body flows into the right atrium, and from the right atrium through the tricuspid valve to right ventricle. The right ventricle pumps the blood through the pulmonary arteries to the lungs. Blood from the lungs returns through the pulmonary veins to the left atrium, and flows from the left atrium through the mitral valve, into the left ventricle. The left ventricle, in turn, pumps the blood through the body. As the heart beats, the atria contract to pump the blood into the ventricles, and then the ventricles contract, during a phase of the heart rhythm referred to as “systole,” to pump the blood through the lungs and through the body.
For proper pumping action, the mitral valve must close when the left ventricle contracts. In a disease state known as mitral valve insufficiency, the mitral valve does not close properly, and a significant portion of the blood in the left ventricle is pumped back from the ventricle into the left atrium when the left ventricle contracts. This diminishes the pumping efficiency of the heart. Mitral valve insufficiency is a relatively common condition and afflicts about 4 million people in the United States alone, with about 250,000 new diagnoses of this condition every year. About 50,000 procedures are done every year to alleviate mitral valve insufficiency.
One surgical approach involves implantation of a porcine valve or a mechanical valve in place of the mitral valve. This procedure requires open heart surgery with long recuperation time, and exposes the patient to high risk of complications. Many of the individuals who need mitral valve repair are elderly, which tends to aggravate the difficulties associated with open heart surgery.
Another common surgical approach to repairing mitral valve insufficiency is annuloplasty. In this approach, a wire is wrapped around the mitral annulus, a ring of collagenous tissue surrounding the opening of the mitral valve, to contract the annulus. This improves the performance of the mitral valve. The mitral valve has two major leaves. If the opening of the valve is contracted, as by annuloplasty, the leaves are positioned closer to one another and form a better seal during systole. Annuloplasty as commonly practiced requires a major thoracic surgery with substantial recuperation time and risk of complications.
As disclosed, for example, in U.S. Pat. Nos. 6,306,133; 6,355,030; 6,485,489; 6,669,687; and 7,229,469, it has been proposed to insert a catheter-like device bearing a transducer such as an electrode or ultrasonic transducer into the heart and actuate the transducer so as to heat the mitral annulus, denature the collagen fibers which constitute the annulus, and thereby shrink the annulus. In theory, such a procedure could bring about shrinkage of the annulus and repair mitral insufficiency in much the same manner as traditional annuloplasty. However, all of these proposals have involved positioning of one or more transducers in contact with the mitral annulus during the procedure. It is difficult to provide such accurate positioning of a transducer within a beating heart. Although it is possible to momentarily halt the heartbeat, perform the procedure and then restart the heart, this adds considerable risk to the procedure. Moreover, localized heating of the annulus by a transducer in contact with the annulus introduces the further risk of damage to the epithelial cells overlying the annulus with attendant risk of thrombus formation after surgery.
Perhaps for these reasons, none of these proposals has been widely adopted. Accordingly, prior to the present invention, there has remained a need for a useful and reliable procedure for mitral valve repair.
One aspect of the present invention provides methods of treating a cardiac valve such as the mitral valve of a human or other mammalian subject. Methods according to this aspect of the present invention desirably include the step of positioning an emitter unit which incorporates an ultrasonic transducer in proximity to the valve without completely occluding the annulus of the valve. The positioning step desirably is performed so that the ultrasonic transducer is spaced apart from the annulus itself. For example, the emitter unit desirably includes an expansible structure such as a balloon, and the ultrasonic transducer is disposed within the expansible structure so that the when the structure is expanded to an operative condition, at least a portion of the structure is spaced apart from the ultrasonic transducer. Thus, when the structure is positioned in engagement with the mitral annulus, the transducer is spaced apart from the mitral annulus. Desirably, the transducer is also cooled by circulating fluid in the balloon to prevent any thrombus formation caused by heating of the transducer during operation.
As further discussed below, the expansible structure may be brought into engagement with the left posterior aspect of the mitral annulus so that the ultrasonic transducer is disposed within the annulus, closer to the posterior aspect than to the anterior aspect of the mitral annulus, and closer to the right aspect of the mitral annulus than to the left aspect, but nonetheless spaced apart from the posterior and left aspects. The transducer may be actuated so as to emit ultrasonic waves. The ultrasonic waves tend to heat the posterior and left aspects of the mitral annulus preferentially. As further discussed below, heating of the posterior aspect is particularly desirable, in that the posterior aspect is rich in collagen and tends to shrink readily with heating.
Preferably, the expansible structure in its expanded condition does not completely occlude the opening of the mitral valve. For example, where the expansible structure incorporates a balloon, the balloon desirably has a maximum diameter smaller than the diameter of the mitral annulus. The step of advancing the emitter unit may include advancing an elongated catheter having the emitter unit mounted thereon into a chamber of the heart, and positioning the catheter so as to position the expansible structure within the annulus of the valve. Where the valve to be treated is the mitral annulus, the catheter desirably is advanced into the left atrium through the right atrium, and through an opening formed in the inter-atrial septum. The step of advancing the catheter may include advancing a delivery sheath into the chamber of the heart and steering a distal region of the sheath, and advancing the catheter through the sheath. For example, the delivery sheath may be advanced into the left atrium, whereupon a distal portion of the sheath is steered in a downward direction, toward the mitral annulus.
The method preferably further includes the step of placing a guidewire extending through the catheter so that the guidewire extends from the left atrium through the mitral valve and into the left ventricle, and the positioning step includes positioning the catheter on the guidewire so that the portion of the catheter bearing the emitter unit is at least partially positioned within the mitral annulus by the guidewire.
As further discussed below, the steerable sheath desirably in combination with the guidewire provides a relatively simple and reliable way of positioning the emitter unit, which allows the emitter unit to remain in place in the beating heart long enough to perform the procedure.
Methods of treating mitral valve insufficiency according to a further aspect of the invention desirably include the step of preferentially applying energy to a selected portion of the mitral annulus, which portion is remote from the aortic valve, so as to heat and contract collagen in that portion of the annulus and thereby shrink the mitral annulus. Methods according to this aspect of the invention may include steps similar to those discussed above, and preferably include applying energy to the mitral annulus by positioning a transducer spaced from the selected portion of the annulus, but closer to the selected portion of the annulus than to other portions of the annulus, and actuating the transducer. Most preferably, the transducer is an ultrasonic transducer.
Yet another aspect of the invention provides apparatus for treating a cardiac valve of a mammalian subject. Apparatus according to this aspect of the invention desirably includes an elongated catheter having proximal and distal regions and an emitter unit including an ultrasonic transducer and an expansible structure carried on the distal region of the catheter. Most preferably, the expansible structure is constructed and arranged to hold the transducer spaced apart from an annulus of the valve when the expansible structure is in an operative, expanded condition, and the emitter unit is disposed in proximity to the valve. The expansible structure most preferably is constructed and arranged so that the expansible unit will not completely occlude the annulus of the valve. The expansible structure also may be arranged to preferentially position the transducer within the mitral valve annulus so that the left posterior aspect of the annulus lies within the near field region of the transducer.
Apparatus according to this aspect of the invention most desirably further includes a delivery sheath having proximal and distal ends, and a sheath steering structure carried on the sheath and operative to selectively bend a region of the sheath. The catheter and the emitter unit desirably are constructed and arranged so that the distal region of the catheter and the emitter unit can be advanced into a chamber of the heart through the sheath. The catheter may also include a catheter steering mechanism carried on the catheter and operative to selectively bend a bend region of the catheter proximal to the emitter unit. The apparatus may also include a guidewire, the catheter being constructed and arranged so that the catheter can be advanced over the guidewire, the guidewire can be advanced through the catheter, or both.
Most preferably, the expansible element includes a balloon, and the balloon has a major diameter smaller than the major diameter of the annulus of the valve to be treated. For example, where the apparatus is intended to treat the mitral valve of a human subject, the balloon desirably has a major diameter of about 30 mm or less. Desirably, the balloon has a proximal portion and a distal portion extending distal to the proximal portion. The distal portion of the balloon desirably has a smaller cross-sectional area than the proximal portion of the balloon when the balloon is in an inflated condition. As further discussed below, the transition between the proximal and distal portions of the balloon may be used to mechanically engage the mitral annulus so as to further stabilize the position of the balloon and transducer during the procedure.
In alternative embodiments the expansible structure comprises two or more individually extendable wires that may to selectively deployed to permit the balloon to be stabilized at a preferred position within the mitral valve annulus.
Further objects, features, and advantages of the present invention will be more readily apparent from the detailed described of the preferred embodiments set forth below, taken in conjunction with the accompanying drawings.
FIG. 1 is a diagrammatic view of a component used in apparatus according to one embodiment of the invention.
FIG. 2 is a fragmentary diagrammatic view of the component shown in FIG. 1 in a different operating condition.
FIG. 3 is a diagrammatic view depicting a further component of the apparatus according to the embodiment of FIGS. 1 and 2.
FIG. 4 is a diagrammatic coronal sectional view of a human heart with the apparatus of FIGS. 1-3 in an operative condition.
FIG. 5 is a diagrammatic axial sectional view of the heart along line 5-5 in FIG. 4, also in conjunction with the apparatus of FIGS. 1-3, but with the atria of the heart removed for clarity of illustration.
FIGS. 6 and 7 are graphs depicting results achieved in certain experiments.
FIG. 8 is a fragmentary diagrammatic sectional view of apparatus according to a further embodiment of the invention.
FIGS. 9A and 9B, are respectively, a plan view depicting apparatus according to an alternative embodiment of the invention and a detailed view of the distal end of the apparatus.
FIG. 10 is a diagrammatic axial sectional view of the heart similar to that of FIG. 5, showing positioning of the apparatus of FIG. 9 within the mitral valve, again with the atria of the heart removed for clarity of illustration.
FIG. 11 is a diagrammatic sectional view depicting apparatus according to yet a further embodiment of the invention.
FIG. 12 is a diagrammatic sectional view depicting apparatus according to yet another embodiment of the invention.
Referring to FIGS. 1-3, apparatus according to one embodiment of the invention includes sheath 10 and energy-emitting catheter 30.
Sheath 10 generally is in the form of an elongated tube having proximal end 12, distal end 14 and proximal-to-distal axis 13. As used in this disclosure with reference to elongated elements for insertion into the body, the term “distal” refers to the end which is inserted into the body first, i.e., the leading end during advancement of the element into the body, whereas the term “proximal” refers to the opposite end. Sheath 10 has interior bore 15 extending between its proximal and distal ends. Desirably, sheath 10 includes relatively stiff wall section 16 extending from its proximal end to juncture 18, and relatively limber distal wall section 20 extending from juncture 18 to distal end 14. Pull wire 22 is slidably mounted in proximal wall structure 16 and connected to distal wall section 20. Pull wire 22 is linked to pull wire control device 24, which can be manipulated by a physician during use of the apparatus. By actuating the pull wire control, the physician can pull on wire 22 and bend the distal region of the sheath in a predetermined direction transverse to the proximal-to-distal direction, as depicted schematically in FIG. 2. The structure of sheath 10 and pull wire control 24 may be generally as shown in U.S. Published Patent Application No. 2006-0270976 (“the '976 Publication”), the disclosure of which is incorporated by reference herein. As discussed in greater detail in the '976 Publication, transition 18 desirably is oblique to the proximal-to-distal axis 13 of the sheath, with stiff section 16 extending to distal-most point 25 on a first side of the sheath, and the pull wire desirably is arranged to bend the sheath only in the direction toward the first side.
Sheath 10 desirably also is arranged so that at least the proximal section is “torquable.” That is, at least the proximal section of the sheath is arranged to transmit torsional motion about axis 13 from proximal end 12 along the axial extent of the sheath. Thus, by turning the proximal end of the sheath, the distal end of the sheath can be rotated about proximal-to-distal axis 13. As best appreciated with reference to FIG. 2, when the sheath is in the curved or bent configuration achieved by tension on the pull wire, rotational motion of the distal end will swing the bent section around proximal-to-distal axis 13. Thus, by combined pulling on the pull wire and rotational motion, distal end 14 of the sheath can be aimed in essentially any desired direction. As disclosed in the aforementioned '976 Publication, the pull wire control can be incorporated into a handle which is physically attached to proximal end 12 of the sheath. Thus, the physician can maneuver the sheath by actuating the pull wire control and turning the handle, desirably with one hand, during the procedure.
Referring now to FIG. 3, the inventive apparatus further includes elongated catheter 30 configured to be inserted through interior bore 15 of sheath 10. Catheter 30 has proximal end 32, distal end 34 and proximal-to-distal axis 33. Catheter 32 desirably incorporates principal bore 36 extending from its proximal end to its distal end. The catheter, like sheath 10 discussed above, may incorporate relatively stiff proximal wall portion 38 and relatively limber distal wall portion 40, with transition 42 between the proximal and distal wall sections. The catheter may be equipped with pull wire 44 which is linked to pull wire control 46. These structural features may be similar to those discussed above with reference to the sheath. Here again, the pull wire control may be actuated to bend the catheter in directions transverse to proximal-to-distal axis 33 of the catheter. The catheter also may be torquable about its axis, so that the distal end of the catheter can be bent in directions transverse to proximal-to-distal axis 33 of the catheter, and rotated around the axis as discussed above in connection with sheath 10.
An expansible structure, illustratively in the form of balloon 50 is mounted to distal end 34 of catheter 30. In the inflated, operative condition depicted, the balloon is generally in the form of a surface of revolution about a central axis coincident with proximal-to-distal axis 33 of the catheter. Balloon 50 has proximal section 52 with diameter dp of about 20 mm, and distal section 54 which has a maximum diameter dd at juncture 56 between distal section 54 and proximal section 52. Distal section 54 tapers inwardly from this diameter to tip 58 at the distal end of the balloon. The balloon has a relatively abrupt change in diameter over relatively short transition 60 between the proximal section and the distal section. Desirably, the balloon is formed from a polymer such as nylon and has a wall thickness of about 8 microns to about 30 microns. The dimensions of the balloon are given in the inflated condition shown in FIG. 3. When deflated, the balloon desirably collapse inwardly to form a relatively small diameter structure. The balloon may be fabricated by blow-molding using techniques that are known in the art.
A tubular, cylindrical ultrasonic transducer 66 is mounted inside balloon 50. Transducer 66 desirably is coaxial or nearly coaxial with the balloon, and is arranged so that the transducer extends axially over at least part of the transition region 60 of the balloon. The axial center point of the transducer may be disposed at an axial location near the juncture between proximal portion 52 and distal portion 54 of the balloon, so that part of the axial length of the transducer is disposed within proximal potion 52 and part of the axial length of the transducer is disposed within distal portion 54. Merely by way of example, transducer 66 may have an axial length of about 6 mm and an outside diameter of about 2-3 mm. The proximal end of the transducer may be in transition region 60 or in proximal region 52 of the balloon. Transducer 66 is carried on tubular metallic support 68 extending from distal end 34 of catheter 30 to tip 58 of the balloon. Support 68 defines an interior bore (not shown) which communicates with main bore 36 of catheter 30. The tubular support 68 extends to distal tip 58 of the balloon so that the interior of tubular support 68 communicates with the exterior of the balloon through port 70 at the distal tip of the balloon. Transducer 66 is mounted on the support so that interior wall 72 of the tubular transducer is spaced apart from exterior wall of support 68. The space between the interior of the transducer and the exterior of the support communicates with the interior space within balloon 50. As disclosed, for example, in U.S. Published Patent Application No. 20060270975, the disclosure of which is incorporated by reference herein, support 68 may include telescopic elements which move axially with respect to one another to accommodate inflation and deflation of the balloon. Transducer 66 desirably is formed from a ceramic piezoelectric material. The tubular transducer has metallic coatings (not shown) on its interior and exterior surfaces. These metallic coatings are connected to a ground wire and a signal wire (not shown) which extend through wiring support tube 74 to the distal end of the catheter. These wires extend through catheter 30 to the proximal end of the catheter, and are configured to be connected to ultrasonic excitation source 76. Metallic support tube 68 and transducer 66 desirably are configured so that the interior surface of the tubular transducer is spaced apart from the exterior surface of tube 68 by a gap distance which corresponds to approximately one-half the wavelength of the ultrasonic energy to be applied, i.e., about 83 microns for 9 MHz ultrasonic energy propagating in water. As further discussed below, this promotes efficient operation of the transducer, with ultrasonic energy reflected at the exterior surface of support tube 66 reinforcing ultrasonic energy propagating within the transducer, so as to provide ultrasonic energy directed outwardly from external surface 66 of the transducer.
The interior space within balloon 50 is connected to circulation device 80 for circulating a liquid, preferably an aqueous liquid, through the balloon. Device 80 includes inflow pump 82 and outflow pump 84. The inflow pump is connected to inflow passage 86 extending through catheter 30 to the balloon, whereas outflow pump 84 is connected to separate outflow passage 88 extending through the catheter to the balloon. Pumps 82 and 84 are connected to coolant circuit 90 for supplying a liquid coolant, desirably an aqueous liquid such as saline solution. The coolant circuit 90 may include elements such as a tank for holding the circulating coolant, a refrigerating coil, or the like for providing a supply of liquid at a controlled temperature, desirably at or below body temperature. The circulation device also includes a control circuit (not shown) for controlling the flow into and out of the balloon. Merely by way of example, the control elements may include motor control devices linked to drive motors associated with pumps 84 and 82 for controlling the speed of operation of the pumps. Such motor control devices can be used, for example, where the pumps are positive displacement pumps such as peristaltic pumps. Alternatively or additionally, the control elements may include structures such as controllable valves connected in the fluid circuit for varying resistance of the circuit to fluid flow. A pressure sensor (not shown) optionally may be mounted in the balloon and electrically connected to the control circuitry. As further discussed below, during operation, circulation device 80 continually circulates the aqueous fluid through the balloon and maintains the balloon under a desired pressure, most preferably about 3 pounds per square inch (20 Kpa).
Referring now to FIGS. 4 and 5, in a method according to one embodiment of the invention, a conventional device such as a Brockenbaugh needle is advanced through the venous system as, for example, through the inferior vena cava and into the right atrium. The needle is used to form a puncture P (FIG. 4) through the inter-atrial septum IAS dividing the right atrium RA from the left atrium LA. After the puncture the needle is withdrawn and sheath 10 is advanced over a dilator. Guidewire 92 may be advanced into the left atrium, and optionally through the mitral valve MV into the left ventricle.
Sheath 10 then is advanced over guidewire 92 until distal end 14 of the sheath extends into the left atrium through puncture P. During this step, the dilator (not shown) may be disposed within bore 14 of sheath 10, so that the dilator surrounds the guidewire and the sheath surrounds the dilator. Once the sheath has been advanced into the left atrium, the dilator may be removed. With balloon 50 in a deflated condition, catheter 30 is advanced over guidewire 92 and through bore 14 of sheath 10. During this advancement, the guidewire extends through port 70 and through support tube 68 and main bore 36 of the catheter. Catheter 30 is advanced until distal end 34 of the catheter and balloon 50 project out from the distal end of sheath 10. Once balloon 50 is disposed within the left atrium, circulation apparatus 80 (shown in FIG. 1) is actuated to inflate the balloon to the desired pressure, desirably about 3 psi (20 Kpa).
Sheath 10 is steered so as to aim the distal end of the sheath downwardly toward the mitral valve MV and rearwardly, toward the posterior surface of the heart and the posterior aspect of the mitral valve ring, also referred to as the annulus fibrosus. This is accomplished by bending the distal end of the sheath using pull wire 22 and pull wire control as discussed above with reference to FIGS. 1 and 2. If catheter 30 is equipped with a pull wire, as discussed above with reference to FIG. 3, the distal tip of the catheter also may be bent and turned so as to aim it posteriorly. Because the sheath extends into the left atrium from the right atrium, the balloon tends to lodge against the left side of the mitral valve ring. The steering operations may also be used to promote disposition of the balloon towards the left side of the mitral valve ring.
Guidewire 92 is positioned such that the guidewire extends through the mitral valve and into the left ventricle. The guidewire may extend further and curve back into the aorta through the aortic valve. The combined effects of the guidewire, the steerable sheath, and, if employed, the steerable catheter all tend to position balloon 50 generally in the location illustrated in FIG. 4, with the balloon extending through the mitral annulus MA of the mitral valve MV, with distal region 54 of the balloon disposed between the leaflets LV of the mitral valve.
Balloon 50 is configured so that juncture 56 tends to engage the mitral annulus. This engagement is facilitated by transition 60 between distal portion 54 and proximal portion 52 of the balloon, and is further facilitated by maintaining a moderate pressure within the balloon, which permits balloon 50 to be indented to some degree by the mitral annulus. This physical engagement between the balloon and the mitral annulus helps to maintain the balloon in the desired operative position relative to the heart. Also, engagement of the balloon is reliably maintained by continued biasing of the balloon into engagement with the mitral annulus by the sheath and catheter, and by the guidewire. Thus, the balloon can be retained in the operative position shown while the heart continues to beat.
With the balloon in the operative position, ultrasonic transducer 66 is aligned with the mitral annulus, but spaced therefrom. That is, radial lines directed outwardly from the outer surface of transducer 66, in a plane perpendicular to the axis of the tubular transducer, would intercept the mitral annulus.
The desired position of the lumen and transducer is further illustrated in FIG. 5, where the heart is seen in an axial view from the top, with the atria and associated structures removed for ease of illustration. Note that balloon 50 is lodged against the mitral annulus, closer to the left side of the mitral annulus than to the right side, and closer to the posterior aspect of the mitral annulus than to the anterior aspect. Transducer 66 is held spaced apart from the mitral annulus, but is disposed closer to the posterior and left aspects of the mitral annulus than to the anterior and front aspects. For example, the radial distance RMIN from the surface of transducer 66 to the left posterior aspect of the mitral annulus may be on the order of 1 cm. The corresponding distances from the surface of transducer 66 to other locations around the mitral annulus are greater. For example, the distance RAV from the surface of transducer 66 to the aortic valve may be on the order of 2 cm or more.
Preferably, balloon 50 does not completely occlude the mitral annulus, and thus does not completely occlude blood flow from the left atrium into the left ventricle. Moreover, the maximum diameter of the balloon is less than the maximum diameter of the mitral annulus, such that leaflets LV of the mitral valve provide reasonable sealing of the mitral valve against backflow from the left ventricle into the left atrium during systole. The leaflets may bear on the balloon and on one another during systole. The smooth surfaces of the balloon minimize damage to the leaflets. Because the heart remains functional while the balloon is in its operative position, the balloon may be retained in this operative condition for a sufficient length of time, for example, several minutes, to perform the procedure. The physician can verify proper placement of the balloon using fluoroscopic or other imaging techniques. To enhance such fluoroscopic techniques, the liquid circulated through the balloon may include a radiological non-ionic contrast agent. Alternatively, placement of the balloon can be visualized by transesophageal echocardiographic imaging, also known as TEE imaging, or other echocardiographic technique. When an echocardiographic technique is utilized, balloon 50 may be initially filled with a fluid containing an ultrasonic contrast medium to allow for easy visualization. The balloon is manipulated as necessary under visualization and thereby positioned in the heart. If an ultrasonic contrast medium is employed, it should be purged from within the first balloon and replaced by a liquid which does not attenuate or reflect ultrasound before actuation of the ultrasonic transducer.
With the balloon and transducer in the operative position, ultrasonic excitation source 76 (FIG. 1) actuates transducer 66 to emit ultrasonic waves. Merely by way of example, the ultrasonic waves may have a frequency of about 1 MHz to a few tens of MHz, most typically about 9 MHz. The transducer typically is driven to emit, for example, about 10 watts to about 100 watts of acoustic power, most typically about 30 to about 40 watts. The actuation is continued for about 20 seconds to about a minute or more, most typically about 40 seconds to about 90 seconds. Optionally, the actuation may be repeated several times as, for example, about 5 times. The frequencies, power levels, and actuation times may be varied from those given above.
The ultrasonic waves generated by the transducer propagate generally radially outwardly from the transducer, outwardly through the liquid within the balloon to the wall of the balloon and into the surrounding blood and tissue. The ultrasonic waves impinge on the tissues of the heart surrounding the balloon, and particularly on the mitral annulus. Propagation of the ultrasonic waves is essentially independent of contact between the balloon and the solid tissues of the heart, such as the mitral annulus. Because all of the tissues, the liquid within the balloon and the blood surrounding the balloon have approximately the same acoustic impedance, there is little or no reflection of ultrasonic waves at interfaces between the liquid within the balloon and the blood outside the balloon; at interfaces between the blood and the tissue; or at the interface between the saline within the balloon and the solid tissue in areas where the balloon does contact the mitral annulus.
Essentially all of the mitral annulus lies within the “near field” region of the transducer. Within this region, the outwardly spreading cylindrical beam of ultrasonic waves tends to remain collimated and has an axial length (the dimension of the beam perpendicular to the plane of the drawing in FIG. 5) approximately equal to the axial length of the transducer. For a cylindrical transducer, the extent of the near field region is defined by the expression L2/λ, where L is the axial length of the transducer and λ is the wavelength of the ultrasonic waves. At distances from the transducer surface greater than L2/λ, the beam begins to spread axially to a substantial extent. However, for distances less than L2/λ, the beam does not spread axially to any substantial extent. Therefore, within the near field region, at distances less than L2/λ, the intensity of the ultrasonic waves decreases linearly, in proportion to distance from the transducer surface, as the beam spreads radially. Thus, the posterior and left regions of the mitral annulus receive substantially more intense ultrasonic waves than the anterior and right regions. This is advantageous, inasmuch as the posterior and left regions contain particularly high concentrations of collagen fibers. The ultrasonic energy directed into these regions is particularly effective in shrinking the mitral annulus. Moreover, the moderate levels of ultrasonic energy directed towards the front and right aspects of the mitral annulus are unlikely to damage sensitive structures such as the aortic valve disposed in proximity to the front and right aspects of the mitral annulus.
The ultrasonic energy applied by the transducer is effective to heat and thus denature collagen fibers within the mitral annulus, thereby shrinking the annulus. It is believed that the shrinkage occurs principally in the left and posterior aspects of the mitral annulus. Because the transducer is spaced apart from the mitral annulus, the ultrasonic energy is applied over the entire mitral annulus simultaneously. There is no need for extreme precision in positioning of the balloon and transducer relative to the heart. Thus, the procedure is relatively simple and reliable. The mitral annulus tends to shrink to some extent immediately upon application of the ultrasonic energy; some additional shrinkage may occur during the weeks following treatment. Shrinkage of the mitral annulus tends to improve the sealing action of the leaflets and reduce or cure mitral valve insufficiency.
Because the ultrasonic energy is dissipated and converted to heat principally inside the mitral annulus, rather than at its surface, the procedure does not damage the surface of the heart which is in contact with the blood, and hence does not provoke thrombus formation. Circulation of the cooled liquid through the balloon during the procedure helps to cool the transducer and essentially prevents direct heat transfer between the transducer and the epithelial lying at the surface of the mitral annulus where the lining contacts the balloon. Those regions of the epithelium which are not in contact with the balloon are cooled by blood flowing over them during the procedure with continued operation of the heart.
Because the procedure can be performed rapidly, the balloons need not be maintained in position for a prolonged time. Additionally, because the procedure does not require intimate contact between the balloon and the mitral annulus or other heart structures, the procedure, including application of the ultrasonic energy, can be performed while the heart continues to beat. Further, balloon 50 is designed to minimize the amount of energy that may be misdirected away from the mitral annulus, to the mitral leaflets or other tissues not targeted by the therapy.
After completion of the ultrasonic application procedure, the balloon is deflated, and the apparatus is withdrawn from the subject's body.
Four dogs are treated using apparatus and techniques substantially as described above with reference to FIGS. 1-5. The dimensions of the mitral annulus are measured in vivo by imaging techniques pretreatment, immediately post-treatment and at one, two, three, and four weeks post-treatment. The results are as indicated in FIGS. 6 and 7, and demonstrate substantial shrinkage of the mitral annulus. The dogs did not evidence adverse effects from the procedure. Their circulation and cardiac rhythm remained intact after the procedure. Upon dissection, the heart did not exhibit scarring of the epithelial lining.
Referring now to FIG. 8, apparatus according to a further embodiment of the invention is described, and incorporates balloon 150 and transducer 166 mounted on distal end 134 of a catheter. In this embodiment, however, balloon 150, in the inflated condition as depicted, has narrow section 100 surrounding transducer 166 and distal region 102 distal to the narrow section, the distal section being of slightly larger diameter than narrow section 100. The balloon also has proximal section 104 proximal to the narrow section. In this embodiment as well, the shape of the balloon facilitates engagement of the balloon with the mitral annulus and stable positioning of the apparatus during use.
Referring now to FIGS. 9A, 9B and 10, a further alternative embodiment of the inventive apparatus is described, including catheter 170, which may be used with or without sheath 10 described above. Catheter 170 includes elongated shaft 171, which may be steerable as described above, having proximal end 172 and distal end 174. Balloon 175, which illustratively is a double-lobed balloon as depicted in FIG. 8, is disposed adjacent distal end 174, and surrounds ultrasonic transducer 176. Balloon 175 is coupled via inflation port 177 to circulation circuit 90 (FIG. 1) which inflates and circulates coolant through the balloon. As for preceding embodiments, balloon 175 is inserted in a deflated state and then inflated with an aqueous liquid, such as saline solution, which surrounds transducer 176 and conducts ultrasonic energy from transducer 176 to the mitral annulus. Ultrasonic transducer is similar in construction to that described with respect to the embodiment of FIG. 3, and emits ultrasonic energy in a substantially radial direction in the near field region, as described above.
Catheter 170 further includes individually movable struts 180 and 182 that extend from proximal end 172 to distal end 174 through interior lumens (not shown) of the catheter body. Struts 180 and 182 exit the lumens via outlets 184 at proximal end 172, and may include compression rings, thumb screws or other suitable means to lock the struts at a selected position. The distal ends of struts 180 and 182 exit through skives 186 in the exterior wall of catheter 170 at a location proximal of balloon 175, pass around the outside of balloon 175, and are fastened to distal end 174 of catheter 170. Struts 180 and 182 preferably comprise a strong, resilient and flexible plastic material, or a metal or metal alloy wires, such as a superelastic nickel-titanium alloy, and may have a circular, oval or rectangular cross-section. While two struts 180 and 180 are depicted in FIG. 9, it is to be understood that a greater or lesser number of struts may be employed in catheter 170.
Referring to FIG. 9B, struts 180 and 182 are slidably disposed in the lumens of catheter 170 and configured to be independently moved from a delivery state, in which the struts are collapsed against deflated balloon 175, to a deployed state, in which each of struts 180 and 182 is extended by advancing it in a distal direction through its respective outlet 184 and skive 186. In this manner, the distal region of each strut 180 and 182 selectively may be caused to bow outward in the deployed state (as indicated by arrows in FIG. 9B). By individually adjusting the extent to which the distal regions of struts 180 and 182 bow outward, the clinician can adjust the positioning of balloon 175, and thus transducer 176, relative to the surrounding tissue. As illustratively depicted in FIG. 9B, strut 182 may be extended to a much greater extent than strut 180, thereby causing balloon 175 and transducer 176 to be positioned closer to strut 180 than to strut 182.
As further illustrated in FIG. 10, when catheter 170 is deployed in the mitral valve, struts 180 and 182 when expanded will extend to the commissures of the mitral valve leaflets. Struts 180 and 182 then may be individually adjusted to position balloon 175 and transducer 176 at the location preferred by the methods of the present invention, e.g., so that the left posterior aspect of the mitral annulus is in the near field region of transducer 176, as described for the embodiment of FIGS. 1-5. Because struts 180 and 182 preferably are formed from a strong, resilient and flexible material, they are capable of accommodating motion of the beating heart while retaining the balloon and transducer at a selected location for the duration of the treatment. Once the mitral annulus has been reduced a selected amount via deposition of ultrasonic energy, as determined, for example, using fluoroscopic imaging, balloon 175 may be deflated. Struts 180 and 182 then may be collapsed to the delivery state, and catheter 170 may be removed.
In the embodiment of FIGS. 9 and 10, balloon 175 illustratively includes the dual-lobed shape depicted in FIG. 8, and when inflated the narrowed region of the balloon assists in longitudinally positioning the transducer relative to mitral annulus MA. In further alternative embodiments, balloon 175 may include a larger proximal region and narrower distal region, like balloon 50 of the embodiment of FIG. 1, or may include a balloon of uniform diameter along its length. Balloon 175 further may include a proximal-facing or distal-facing reflector element, as described for additional embodiments herein below. Preferably, however, balloon 175 does not fully occlude the mitral valve when deployed, and thus permits uninterrupted flow of blood through the left side of the heart during the procedure.
Referring now to FIG. 11, apparatus according to yet another embodiment of the invention includes catheter 230 having balloon 250 and first transducer 266 similar to the corresponding features of the embodiments discussed above with reference to FIGS. 1-5. Catheter 230 further includes second transducer 202 mounted proximally to transducer 266. Second balloon 204 surrounds a portion of the proximal region of balloon 250 aligned with second transducer 202. A separate lumen (not shown) is provided in catheter 230 for inflation and deflation of second balloon 204.
In operation, second balloon 204 is inflated with a gas such as carbon dioxide. Balloon 250 in its inflated condition is configured to have parabolic surface 206 in the regions surrounding transducer 202. As described, for example, in U.S. Pat. No. 6,635,054 and U.S. Published Patent Application No. 2004-0176757, the disclosures of which are hereby incorporated by reference, the interface between the liquid inside first balloon 250 and the gas inside second balloon 204 forms a reflector for ultrasound. The ultrasonic energy emitted from second transducer 202 is reflected at this interface and directed substantially into annular focal region 208, forward of transducer 202 and outside of balloon 250.
As described in the patent and publication mentioned in the preceding paragraph, the forwardly directed ultrasound energy may be used to form a substantially ring-like lesion in cardiac tissue. For example, the balloon may be positioned so that focal region 208 lies within the cardiac tissue surrounding a pulmonary vein, and transducer 202 may be actuated to direct ultrasonic energy into this focal region, thereby ablating the cardiac tissue around the pulmonary vein, e.g., to treat atrial fibrillation. First transducer 266 can be used in the manner discussed above to treat mitral insufficiency. The ultrasonic energy from first transducer 266 propagates radially outwardly in the manner described above, and does not encounter the reflective interface formed by the gas in second balloon 204.
Catheter 230, which may be configured to be steerable similarly to sheath 10, may be used alone or in conjunction with a steerable sheath, like sheath 10 described above, to reposition the apparatus from the position required for treatment of atrial fibrillation to the position required for treatment of mitral insufficiency, or the reverse. The capability of treating both atrial fibrillation and mitral insufficiency with a single catheter-based device provides a significant advantage, inasmuch as a significant proportion of patients who suffer from atrial fibrillation also suffer from mitral insufficiency, and vice-versa. Gas-filled second balloon 204 can be readily visualized in echocardiographic techniques, as it is highly reflective to ultrasound.
In a variant of this embodiment, first and second transducers 202 and 266 may be replaced by a single transducer which can be moved by the operator between the positions indicated for transducers 202 and 266. In a further variant, the emitter structure may include only a single transducer at the location indicated for second transducer 202. In this variant, the emitter structure is arranged to emit ultrasound only in the forward or distal direction, into ring-like focal region 208. For treatment of mitral valve insufficiency, the balloon may be positioned in the atrium, with the distal end of the balloon extending through the mitral annulus so that focal region 208 is aligned with the mitral annulus.
In a further variant, the balloon may be reversed, so that second balloon 204 is positioned within the ventricle, between the leaflets of the mitral valve. In this arrangement, the ultrasonic energy is emitted in the retrograde direction, toward the atrium. In this configuration, gas-filled second balloon 204 blocks transmission of ultrasonic energy to the leaflets, and thus prevents damage to the leaflets. Thus, the possibility of misdirecting energy into the mitral leaflets and the left ventricle is largely eliminated.
Numerous other variations and combinations of the features discussed above can be utilized without departing from the present invention as defined by the claims. For example, expansible structures other than those described above may be used. For example, an expandable basket-like structure can be used in place of the balloon. In still other embodiments, the emitter structure can include reflective or blocking structures for selectively directing ultrasonic waves from the transducer over only a limited range of radial directions. For example, the apparatus of FIG. 12 includes reflective balloon 302 which may be filled with a gas, for selectively directing the ultrasonic waves from transducer 366 over only a limited range of radial directions. Here again, the ultrasound passes through balloon 350 to impinge on the surrounding mitral annulus.
In still other arrangements, the ultrasonic transducer itself may have a directional emission pattern. Another embodiment is to utilize a transducer designed to be activated by different frequencies at designed sectors of its circumference. By varying the wall thickness of the transducer, it will resonate at different frequencies thus allowing for the electronic control of emitted energy to create an optimal energy pattern that is asymmetric.
Alternatively, asymmetric energy delivery can be achieved using segmented transducers (example: individual arc-lengths less than 360 degrees when combined form a 360 degree tubular transducer). In still other embodiments, focusing devices, such as lenses and diffractive elements can be employed. An annular lens surrounding a cylindrical transducer as shown, for example in U.S. Published Patent Application No. 2002-0068885, the disclosure of which is hereby incorporated by reference herein, may be used to narrow the axial extent of the emitted ultrasonic waves.
The route by which the apparatus is introduced into the heart can be varied from that discussed above. However, the atrial approach offers a safety advantage over a retrograde approach through the aortic valve because the risk of entangling the catheter with the chordae tendinae is much higher in a retrograde approach to the mitral valve through the ventricle. Also, it is not essential to use a catheter to place the expansible device. The emitter structure, including the transducer and the balloon or other expansible device as described above can be mounted on a short and relatively inflexible handle, so that the emitter structure can be placed by a minimally invasive surgical technique.
The state of the mitral annulus can be monitored by ultrasound imaging during the treatment. During treatment, the collagenous tissue changes its physical properties, and thus its ultrasound reflectivity when heated. These changes in tissue ultrasound reflectivity can be observe using ultrasonic imaging to monitor the formation of the desired lesion in the mitral valve. Doppler ultrasound can be used to monitor the blood flow during the procedure. Ultrasonic transducers for these purposes can be carried on the same catheter which carries the emitter unit, or on separate catheters or probes. Other imaging modalities which can detect heating can also be used to monitor the treatment. For example, magnetic resonance imaging can detect changes in temperature.
In a further variant, ultrasonic range detection can be used to monitor the size of the mitral annulus during treatment. For example, pinging devices can be mounted adjacent to transducer 66 (FIG. 3). One configuration is to use two-pair devices at diametrically opposite locations, on opposite sides of the central axis of the balloon. The purpose of the pinging devices is to monitor the acute progress (mitral annulus shrinkage) during the course of ablation. The ultrasound pinging devices measure relative distance to the surrounding tissue. By comparing the relative distance between the opposite walls (e.g., anterior-posterior) measured by pinging devices, the operator can monitor the resultant mitral annulus shrinkage to a preplanned size.
In yet another variant, the application of the ultrasonic energy can be gated to the cardiac cycle. The cardiac cycle can be monitored by conventional EKG techniques, by ultrasonic blood flow measurement, or by other techniques. Excitation unit 76 may be arranged, for example, to deliver the ultrasonic waves only at a preselected point in each cardiac cycle.
The apparatus and methods discussed above are particularly useful in treating mitral valve insufficiency, but also may be used to treat other valves in the circulatory system as, for example, the tricuspid valve of the heart.
US4084582 11 Mar 1976 18 Abr 1978 New York Institute Of Technology Ultrasonic imaging system
US4185501 13 Feb 1978 29 Ene 1980 Second Foundation Ultrasonic sector scanner
US4194510 15 Jun 1978 25 Mar 1980 Second Foundation, Inc. Ultrasonic focusing system
US4387720 29 Dic 1980 14 Jun 1983 Hewlett-Packard Company Transducer acoustic lens
US4391281 6 Ene 1977 5 Jul 1983 Sri International Ultrasonic transducer system and method
US4402307 31 Oct 1980 6 Sep 1983 Datascope Corp. Balloon catheter with rotatable energy storing support member
US4433692 11 May 1982 28 Feb 1984 Olympus Optical Co., Ltd. Ultrasonic diagnosis device
US4680499 9 Abr 1986 14 Jul 1987 Hitachi, Ltd. Piezoelectric ultrasonic transducer with acoustic matching plate
US4685334 27 Ene 1986 11 Ago 1987 The Babcock & Wilcox Company Method for ultrasonic detection of hydrogen damage in boiler tubes
US4691714 8 Abr 1986 8 Sep 1987 Adamtek Corporation Rheological testing apparatus and method
US4800316 22 Dic 1987 24 Ene 1989 Shanghai Lamp Factory Backing material for the ultrasonic transducer
US4914510 23 Dic 1988 3 Abr 1990 North American Philips Corporation Method for improving the white field uniformity of a projection color TV using CRTs having interference filters, projection color TV and CRTs resulting from the method
US4983169 2 Mar 1989 8 Ene 1991 Yuichi Furukawa Catheter for angiography
US5105116 30 May 1990 14 Abr 1992 Seikosha Co., Ltd. Piezoelectric transducer and sound-generating device
US5175711 2 Ene 1992 29 Dic 1992 Hitachi, Ltd. Surface acoustic wave apparatus and method of productivity and adjustment of the same
US5209299 4 Feb 1992 11 May 1993 Ayres Robert N Multiple chamber chemical injection system
US5305731 13 Oct 1992 26 Abr 1994 Siemens Aktiengesellschaft Apparatus for generating acoustic wave having a liquid lens with an adjustable focal length
US5305755 4 Mar 1992 26 Abr 1994 Fujitsu Limited Ultrasonic probe, having transducer array capable of turning around its aperture axis and having a convex lens comprising a viscous resin
US5364388 14 Sep 1992 15 Nov 1994 Koziol Jeffrey E Beam delivery system for corneal surgery
US5488955 21 Oct 1993 6 Feb 1996 Hewlett Packard Company Magnetostriction transducer and an intraoperative probe for acoustic imaging
US5513639 5 Oct 1994 7 May 1996 Fujitsu Limited Balloon type ultrasonic diagnostic probe
US5553611 20 Ene 1995 10 Sep 1996 Endocardial Solutions, Inc. Endocardial measurement method
US5596989 27 Dic 1994 28 Ene 1997 Olympus Optical Co., Ltd. Ultrasonic probe
US5655539 26 Feb 1996 12 Ago 1997 Abbott Laboratories Method for conducting an ultrasound procedure using an ultrasound transmissive pad
US5767692 29 Mar 1996 16 Jun 1998 Circuit Line Spa Device for converting the test point grid of a machine for electrically testing unassembled printed circuit boards
US5782900 23 Jun 1997 21 Jul 1998 Irvine Biomedical, Inc. Catheter system having safety means
US5817018 27 Ene 1997 6 Oct 1998 Aloka Co., Ltd. Method for measuring speed of sound in tissue and tissue assessment apparatus
US5840066 22 Oct 1996 24 Nov 1998 Tokai Kobunshi Kagaku Kabushikigaisha Infusion catheter
US5840076 12 Abr 1996 24 Nov 1998 Ep Technologies, Inc. Tissue heating and ablation systems and methods using electrode structures with distally oriented porous regions
US5868741 8 Jun 1998 9 Feb 1999 Irvine Biomedical, Inc. Ablation catheter system having fixation tines
US5868779 15 Ago 1997 9 Feb 1999 Ruiz; Carlos E. Apparatus and methods for dilating vessels and hollow-body organs
US5891137 21 May 1997 6 Abr 1999 Irvine Biomedical, Inc. Catheter system having a tip with fixation means
US5916170 21 Sep 1998 29 Jun 1999 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for curvature detection in vessels from phase shifts of a plurality of input electrical signals
US5954751 15 Ene 1998 21 Sep 1999 Intermedics Inc. Implantable defibrillator with stacked transistor subassemblies
US6013053 17 May 1996 11 Ene 2000 Qlt Photo Therapeutics Inc. Balloon catheter for photodynamic therapy
US6017274 2 Sep 1997 25 Ene 2000 Automotive Racing Products, Inc. Method of forming a fastener
US6059423 16 Mar 1998 9 May 2000 Knopick; Darlene J. Decoratively illuminated carrying device
US6094988 16 Feb 1996 1 Ago 2000 Precision Acoustics Limited Electrical coupling for piezoelectric ultrasound detector
US6106474 19 Nov 1997 22 Ago 2000 Scimed Life Systems, Inc. Aerogel backed ultrasound transducer
US6123456 1 Jul 1998 26 Sep 2000 General Electric Company Catalytic hydrogenation to remove gas from x-ray tube cooling oil
US6163716 2 Nov 1999 19 Dic 2000 Ep Technologies, Inc. Cardiac mapping and ablation systems
US6166092 7 Jun 1995 26 Dic 2000 Alliance Pharmaceutical, Corp. Fluorocarbon compositions for pulmonary therapy
US6196059 11 Ago 1998 6 Mar 2001 Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Piezoelectric resonator, process for the fabrication thereof including its use as a sensor element for the determination of the concentration of a substance contained in a liquid and/or for the determination of the physical properties of the liquid
US6200269 28 May 1998 13 Mar 2001 Diasonics, Ultrasound, Inc. Forward-scanning ultrasound catheter probe
US6208142 7 Dic 1998 27 Mar 2001 Transurgical, Inc. Magnetic resonance apparatus and methods with shim adjustment
US6233477 9 Ago 1999 15 May 2001 Irvine Biomedical, Inc. Catheter system having controllable ultrasound locating means
US6278351 6 Ene 2000 21 Ago 2001 Transurgical, Inc. Multi-coil MRI magnet
US6280402 18 Jun 1999 28 Ago 2001 Kabushiki Kaisha Toshiba Ultrasound therapeutic apparatus
US6282949 10 Mar 1998 4 Sep 2001 Amersham Pharmacia Biotech Ab Apparatus for detection of inhomogeneities in a liquid flow
US6517811 5 Ene 2001 11 Feb 2003 Research Corporation Technologies, Inc. Compounds for cancer imaging and therapy
US6542251 23 Ago 2001 1 Abr 2003 Leica Microsystems Wetzlar Gmbh Illumination and imaging device for multiple spectral regions, and coordinate measuring machine having an illumination and imaging device for multiple spectral regions
US6543274 22 Sep 1999 8 Abr 2003 Robert Bosch Gmbh Sensor array and method for determining the density and viscosity of a liquid
US6601459 25 Oct 2000 5 Ago 2003 Universitat Zurich Method of volumetric blood flow measurement
US6642515 28 Mar 2000 4 Nov 2003 Japan Science And Technology Corporation Method and apparatus for electrospray mass spectrometric analysis
US6656136 25 Oct 2000 2 Dic 2003 Therus Corporation Use of focused ultrasound for vascular sealing
US6764486 24 Abr 2002 20 Jul 2004 Biotronik Mess- und Therapieger{haeck over (a)}te GmbH & Co. Ingenieurbüro Berlin Ablation device for cardiac tissue, especially for forming a circular lesion around a vessel orifice in the heart
US6939309 12 Abr 2000 6 Sep 2005 Endocardial Solutions, Inc. Electrophysiology mapping system
US7004911 24 Feb 2003 28 Feb 2006 Hosheng Tu Optical thermal mapping for detecting vulnerable plaque
US7054685 8 Ago 2002 30 May 2006 Genetronics, Inc. Method and apparatus for reducing electroporation-mediated muscle reaction and pain response
US7189229 6 Ago 2003 13 Mar 2007 Prorhythm, Inc. Balloon alignment and collapsing system
US7599736 19 Jul 2002 6 Oct 2009 Dilorenzo Biomedical, Llc Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease
US7756683 8 Jul 2005 13 Jul 2010 MLU-Monitoring fuer Leben und Umwelt GES.m.b.H. Measuring device and method for measuring at least one environmental parameter
US7824341 19 Sep 2007 2 Nov 2010 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and apparatus for locating the fossa ovalis and performing transseptal puncture
US7864275 13 Ago 2008 4 Ene 2011 Hitachi Displays, Ltd. Liquid crystal display device with a light blocking film formed on a surface of a substrate that surrounds a phase difference film and an orientation film also formed on the substrate surface between the substrate and the phase difference film
US8040612 12 Ene 2009 18 Oct 2011 Koninklijke Philips Electronics N.V. Fluid lens with pressure release system
US20020082594 22 Oct 2001 27 Jun 2002 Cary Hata Injectable biomaterial and methods for use thereof
US20030013968 13 Jul 2001 16 Ene 2003 Todd Fjield Ultrasonic transducers
US20030114901 19 Dic 2001 19 Jun 2003 Loeb Marvin P. Device for treatment of atrioventricular valve regurgitation
US20030138571 11 Dic 2002 24 Jul 2003 Tatsuo Kunishi Method of manufacturing electronic part, electronic part and electroless plating method
US20030150464 18 Dic 2000 14 Ago 2003 Casscells S. Ward Inducing apoptosis of atrial myocytes to treat atrial fibrillation
US20030199767 28 Ago 2002 23 Oct 2003 Cespedes Eduardo Ignacio Methods and apparatus for the identification and stabilization of vulnerable plaque
US20030216794 24 Mar 2003 20 Nov 2003 Hans Becker Therapeutic electrolysis device
US20030236443 20 Mar 2003 25 Dic 2003 Cespedes Eduardo Ignacio Methods and apparatus for the identification and stabilization of vulnerable plaque
US20040044286 29 Ago 2002 4 Mar 2004 Hossack Norman Hugh Ultrasonic imaging devices and methods of fabrication
US20040064091 13 May 2003 1 Abr 2004 Gad Keren Apparatus and methods for treating congestive heart disease
US20040068257 6 Ago 2003 8 Abr 2004 Transurgical, Inc. Balloon alignment and collapsing system
US20040082859 30 Jun 2003 29 Abr 2004 Alan Schaer Method and apparatus employing ultrasound energy to treat body sphincters
US20040101523 20 Oct 2003 27 May 2004 G.D. Searle & Co. Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension
US20040158151 4 Feb 2004 12 Ago 2004 Omnisonics Medical Technologies, Inc. Apparatus and method for an ultrasonic probe device with rapid attachment and detachment means
US20040176699 3 Mar 2003 9 Sep 2004 Volcano Therapeutics, Inc. Thermography catheter with improved wall contact
US20040243102 1 Abr 2004 2 Dic 2004 Scimed Life Systems, Inc. Guide catheter having selected flexural modulus segments
US20040260278 12 Abr 2004 23 Dic 2004 Anderson Scott C. Apparatus and method for ablating tissue
US20050080459 9 Oct 2003 14 Abr 2005 Jacobson Jerry I. Cardioelectromagnetic treatment
US20050192638 28 Jul 2004 1 Sep 2005 Mark Gelfand Methods and devices for renal nerve blocking
US20050209548 19 Mar 2004 22 Sep 2005 Dev Sukhendu B Electroporation-mediated intravascular delivery
US20050209588 17 May 2005 22 Sep 2005 Crum, Kaminski & Larson, Llc HIFU resculpturing and remodeling of heart valves
US20050209642 21 Abr 2005 22 Sep 2005 Yoram Palti Treating a tumor or the like with electric fields at different orientations
US20050215949 * 18 May 2005 29 Sep 2005 Endoscopic Technologies, Inc. Multichannel catheter
US20050240170 24 Sep 2003 27 Oct 2005 Therus Corporation Insertable ultrasound probes, systems, and methods for thermal therapy
US20050251127 12 Abr 2005 10 Nov 2005 Jared Brosch Miniature ultrasonic transducer with focusing lens for intracardiac and intracavity applications
US20060009753 16 Sep 2005 12 Ene 2006 Prorhythm, Inc. Thermal treatment methods and apparatus with focused energy application
US20060058711 4 Nov 2005 16 Mar 2006 Prorhythm, Inc. Energy application with inflatable annular lens
US20060064081 13 Sep 2005 23 Mar 2006 Michael Rosinko Ablation device with phased array ultrasound transducer
US20060088705 14 Oct 2005 27 Abr 2006 Alps Electric Co., Ltd. Plating substrate, electroless plating method, and circuit forming method using the same
US20060089674 11 Abr 2003 27 Abr 2006 Walters Richard E Method of treating biological materials with translating electrical fields and electrode polarity reversal
US20060100514 3 Jul 2003 11 May 2006 Prorhythm, Inc. Cardiac ablation using microbubbles
US20060121016 18 Oct 2005 8 Jun 2006 Lee Raphael C Methods and compositions for treatment of free radical injury
US20060121610 25 Ene 2006 8 Jun 2006 The Regents Of The University Of California Controlled electroporation and mass transfer across cell membranes
US20060155344 3 Feb 2003 13 Jul 2006 Ali Rezai Delivery device for stimulating the sympathetic nerve chain
US20060167437 16 Dic 2005 27 Jul 2006 Flowmedica, Inc. Method and apparatus for intra aortic substance delivery to a branch vessel
US20060167499 27 Dic 2005 27 Jul 2006 Standen Ltd Treating a tumor or the like with electric fields at different orientations
US20060189941 28 Feb 2006 24 Ago 2006 Mercator Medsystems, Inc. Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation
US20060189960 7 Sep 2005 24 Ago 2006 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US20060190044 22 Feb 2005 24 Ago 2006 Cardiac Pacemakers, Inc. Cell therapy and neural stimulation for cardiac repair
US20060241524 23 May 2005 26 Oct 2006 Qi Yu Intravascular ultrasound catheter device and method for ablating atheroma
US20060270975 31 May 2005 30 Nov 2006 Prorhythm, Inc. Steerable catheter
US20070066972 19 Oct 2006 22 Mar 2007 Medwaves, Inc. Ablation catheter apparatus with one or more electrodes
US20070083239 23 Sep 2005 12 Abr 2007 Denise Demarais Methods and apparatus for inducing, monitoring and controlling renal neuromodulation
US20070156200 29 Dic 2005 5 Jul 2007 Lilian Kornet System and method for regulating blood pressure and electrolyte balance
US20070208382 2 Mar 2007 6 Sep 2007 Yun Joonkyoo A Methods and compositions for treating a renal associated condition in a subject
US20070244479 11 Abr 2007 18 Oct 2007 St. Jude Medical, Atrial Fibrillation Division, Inc. Electrophysiology Therapy Catheter
US20070249046 20 Abr 2006 25 Oct 2007 Shields Donald J Jr Apparatus and method for the static application of therapeutic ultrasound and stem cell therapy of living tissues
US20070282376 6 Jun 2006 6 Dic 2007 Shuros Allan C Method and apparatus for neural stimulation via the lymphatic system
US20070282407 16 Ago 2007 6 Dic 2007 Ardina, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US20070288070 9 Jun 2006 13 Dic 2007 Imad Libbus Physical conditioning system, device and method
US20080086073 * 10 Oct 2006 10 Abr 2008 Mcdaniel Benjamin Multi-region staged inflation balloon
US20080140150 22 May 2007 12 Jun 2008 Xiaohong Zhou Methods and apparatus for the regulation of hormone release
US20080172049 9 Ago 2006 17 Jul 2008 Koninklijke Philips Electronics, N.V. System and Method For Electrophysiology Regaining Support to Continue Line and Ring Ablations
US20080195092 2 Nov 2007 14 Ago 2008 Kim Daniel H Apparatus and methods for minimally invasive obesity treatment
US20080300588 15 Nov 2006 4 Dic 2008 Koninklijke Philips Electronics, N.V. Automating the Ablation Procedure to Minimize the Need for Manual Intervention
US20090062697 29 Ago 2008 5 Mar 2009 Therus Corporation Insertable ultrasound probes, systems, and methods for thermal therapy
US20090198223 2 Abr 2007 6 Ago 2009 Koninklijke Philips Electronics N.V. Systems and methods for cardiac ablation using laser induced optical breakdown
US20090216286 5 May 2009 27 Ago 2009 Dilorenzo Daniel John Methods and apparatus for neuromodulation and physiologic modulation for the treatment of obesity and metabolic and neuropsychiatric disease
US20090221939 14 Ago 2006 3 Sep 2009 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US20090248011 2 Mar 2009 1 Oct 2009 Hlavka Edwin J Chronic venous insufficiency treatment
US20090306739 9 Ago 2009 10 Dic 2009 Dilorenzo Daniel John Methods and apparatus for neuromodulation and physiologic modulation for the treatment of obesity and metabolic and neuropsychiatric disease
US20100004528 20 Ago 2007 7 Ene 2010 Koninklijke Philips Electronics N. V. Interventional device for rf ablation for use in rf fields
US20100010567 25 Sep 2009 14 Ene 2010 The Foundry, Llc Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
US20100016934 3 Mar 2008 21 Ene 2010 Koninklijke Philips Electronics N.V. Apparatus and method for applying energy within an object
US20100037902 17 Dic 2007 18 Feb 2010 Koninklijke Philips Electronics N. V. Wireless interventional device and a system for wireless energy transmission
US20100041977 7 Sep 2007 18 Feb 2010 Koninklijke Philips Electronics N.V. Catheter and medical assembly
US20100057150 11 Nov 2009 4 Mar 2010 Ardian, Inc. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US20100063492 27 Nov 2007 11 Mar 2010 Koninklijke Philips Electronics N.V. Apparatus, method and computer program for applying energy to an object
US20100130892 10 May 2007 27 May 2010 Prorhythm, In. Ablation device with optimized input power profile and method of using the same
US20100171394 6 Jul 2009 8 Jul 2010 Glenn Richard A Energy harvesting for implanted medical devices
US20100185126 7 Jul 2008 22 Jul 2010 Koninklijke Philips Electronics N.V. Ultrasonic assembly with adjustable fluid lens
US20100259832 10 Dic 2008 14 Oct 2010 Koninklijke Philips Electronics N.V. Adjustable lens system for real-time applications
US20100262130 26 Nov 2008 14 Oct 2010 Koninklijke Philips Electronics N.V. Apparatus, a method and a computer program for applying energy to an object
US20100272398 2 Dic 2008 28 Oct 2010 Koninklijke Philips Electronics N.V. Apparatus, method and computer program for applying energy to an object
US20100274235 27 Nov 2008 28 Oct 2010 Koninklijke Philips Electronics N.V. Apparatus, method and computer program for applying energy to an object
US20100280504 15 Dic 2008 4 Nov 2010 Koninklijke Philips Electronics N.V. Tissue ablation device with photoacoustic lesion formation feedback
US20100290318 12 Abr 2007 18 Nov 2010 Koninklijke Philips Electronics N.V. System for variably refracting ultrasound and/or light
US20110004184 30 Sep 2008 6 Ene 2011 Karl-Heinz Proksch Device for introducing medicine into an infusion container
US20110028798 28 Jul 2009 3 Feb 2011 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Electronically initiating an administration of a neuromodulation treatment regimen chosen in response to contactlessly acquired information
US20110029038 28 Jul 2009 3 Feb 2011 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Determining a neuromodulation treatment regimen in response to contactlessly acquired information
US20110079230 9 Dic 2010 7 Abr 2011 Asthmatx, Inc. Method for treating an asthma attack
US20110086257 8 Jun 2009 14 Abr 2011 Sumitomo Chemical Company, Limited Method for producing lithium complex metal oxide
US20110104060 22 Abr 2010 5 May 2011 Mercator Medsystems, Inc. Treatment of hypertension by renal vascular delivery of guanethidine
US20110118632 15 Nov 2010 19 May 2011 Recor Medical, Inc. Cardiac ablation devices
US20110118714 10 Jul 2009 19 May 2011 Koninklijke Philips Electronics N.V. Safe ablation
US20110118725 11 Nov 2010 19 May 2011 Mayse Martin L Non-invasive and minimally invasive denervation methods and systems for performing the same
US20110130663 19 Oct 2007 2 Jun 2011 Koninklijke Philips Electronics N.V. Symmetric and preferientially steered random arrays for ultrasound therapy
US20110163630 8 Sep 2009 7 Jul 2011 Koninklijke Philips Electronics N.V. Capacitive micromachine ultrasound transducer
US20110166482 7 Mar 2011 7 Jul 2011 Stack Richard S System and method for transvascularly stimulating contents of the carotid sheath
US20110208173 24 Feb 2011 25 Ago 2011 Medtronic Vascular, Inc. Methods for Treating sleep apnea via renal Denervation
US20110208175 24 Feb 2011 25 Ago 2011 Medtronic Vascular, Inc. Methods for Treating Sleep Apnea Via Renal Denervation
US20110237983 3 Jun 2011 29 Sep 2011 Flowcardia, Inc. Ultrasound catheter for disrupting blood vessel obstructions
US20110257512 23 Nov 2009 20 Oct 2011 Koninklijke Philips Electronics N.V. Susceptibility-based local flow detection to control mr-guided ablation using balloon devices
US20110257561 15 Mar 2011 20 Oct 2011 Kona Medical, Inc. Energetic modulation of nerves
US20110257647 24 Jun 2011 20 Oct 2011 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US20110263921 29 Dic 2010 27 Oct 2011 Anthony Vrba Patterned Denervation Therapy for Innervated Renal Vasculature
US20110275962 5 Nov 2009 10 Nov 2011 Koninklijke Philips Electronics N.V. Acoustical switch and catheter comprising acoustical switch
US20110301508 5 Feb 2010 8 Dic 2011 Koninklijke Philips Electronics N.V. Transurethral ultrasound probe for treatment of prostate
US20110301662 9 Jun 2011 8 Dic 2011 Nephera Ltd. Stimulation of the urinary system
US20110313290 2 Mar 2010 22 Dic 2011 Koninklijke Philips Electronics N.V. Catheter, apparatus method and computer program for applying energy to an object
US20120004547 8 Ene 2010 5 Ene 2012 Koninklijke Philips Electronics N.V. Monitoring apparatus for monitoring an ablation procedure
US20120004656 12 Jul 2011 5 Ene 2012 Jerome Jackson Methods and systems for treatment of tissue in a body lumen
US20120016358 26 Sep 2011 19 Ene 2012 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US20120022409 27 Sep 2011 26 Ene 2012 Kona Medical, Inc. Energetic modulation of nerves
US20120059286 7 Sep 2011 8 Mar 2012 Roger Hastings Self-Powered Ablation Catheter for Renal Denervation
US20120065493 15 Mar 2011 15 Mar 2012 Kona Medical, Inc. Energetic modulation of nerves
US20120065554 8 Sep 2011 15 Mar 2012 Michael Pikus Dual Balloon Ablation Catheter with Vessel Deformation Arrangement for Renal Nerve Ablation
US20120078278 30 Nov 2011 29 Mar 2012 Bales Jr Thomas O Battery-Powered Hand-Held Ultrasonic Surgical Cautery Cutting Device
US20120089047 5 Ago 2011 12 Abr 2012 Medtronic Vascular, Inc. Cryoablation apparatuses, systems, and methods for renal neuromodulation
US20120109018 20 Abr 2011 3 May 2012 Kona Medical, Inc. Energetic modulation of nerves
US20120109021 27 Oct 2011 3 May 2012 Roger Hastings Renal denervation catheter employing acoustic wave generator arrangement
US20120116392 26 Oct 2011 10 May 2012 Martin Willard RF Renal Denervation Catheter with Multiple Independent Electrodes
US20120123243 14 Nov 2011 17 May 2012 Roger Hastings Catheter guidance of external energy for renal denervation
US20120123261 23 Sep 2011 17 May 2012 Jenson Mark L Renal Nerve Ablation Using Mild Freezing and Vibration
US20120123303 23 Sep 2011 17 May 2012 David Sogard Minimally Invasive Access for Renal Nerve Ablation
US20120123406 23 Sep 2011 17 May 2012 Kevin Edmunds Self-Expanding Cooling Electrode for Renal Nerve Ablation
US20120215106 3 May 2012 23 Ago 2012 CardioSonic Ltd. Tissue treatment
US20130075928 10 Abr 2012 28 Mar 2013 Texas Instruments Incorporated Integrated circuit and method of making
USD384743 19 Ene 1996 7 Oct 1997 Irvine Biomedical, Inc. Exchangeable catheter handle for inserting a catheter shaft
EP0774276B1 11 Nov 1996 15 Sep 2004 American Medical Systems, Inc. Apparatus and method for transurethral focussed ultrasound therapy
EP0838980B1 24 Oct 1997 8 Mar 2006 Canon Kabushiki Kaisha Glass circuit substrate and fabrication method thereof
EP1042990B1 3 Abr 2000 18 Oct 2006 Medtronic, Inc. Ablation catheter for isolating a pulmonary vein
EP1598024A2 11 Jun 1997 23 Nov 2005 The Spectranetics Corporation Catheter for delivery of electric energy and a process for manufacturing the same
EP2092957B1 28 Jun 2007 5 Ene 2011 Ardian, Inc. Systems for thermally-induced renal neuromodulation
EP2218479A2 28 Jun 2007 18 Ago 2010 Ardian, Inc. Methods and systems for thermally-induced renal neuromodulation
GB2037166B Título no disponible
JP2002078809A Título no disponible
JPH07178173A Título no disponible
JPH10127678A Título no disponible
JPH11218100A Título no disponible
WO1990000420A1 13 Jul 1989 25 Ene 1990 Adrian Charles Rowland Light delivery system
WO1994005365A1 26 Ago 1993 17 Mar 1994 Kleiman Jay H Perfusion dilatation catheter
WO1995019143A1 14 Ene 1994 20 Jul 1995 Paul G. Yock And Robert J. Siegel, A Joint Venture Ultrasonic ablation of stenoses and occlusions with imaging guidance
WO1996000039A1 14 Oct 1994 4 Ene 1996 Ep Technologies, Inc. Systems and methods for sensing temperature within the body
WO1999044523A1 5 Mar 1999 10 Sep 1999 Scimed Life Systems, Inc. Pmr device and method
WO1999052423A9 2 Abr 1999 2 Dic 1999 Bard Inc C R Pulmonary vein ablation catheter
WO2000016850A9 20 Sep 1999 26 Oct 2000 Epicardia Inc Apparatus and method for diagnosis and therapy of electrophysiological disease
WO2000045706A1 2 Feb 2000 10 Ago 2000 Transurgical, Inc. Intrabody hifu applicator
WO2000051683A9 2 Mar 2000 14 Jul 2005 Atrionix Inc Atrial ablator having balloon and sensor
WO2000057495A1 22 Mar 2000 28 Sep 2000 Transurgical, Inc. Ultrasonic transducer, transducer array, and fabrication method
WO2001013357A1 4 Ago 2000 22 Feb 2001 Ekos Corporation Ultrasound assembly for use with a catheter
WO2001037925A3 22 Nov 2000 13 Dic 2001 Boston Scient Ltd Atrial annulus ablation loop with expandable pusher
WO2001080723A2 24 Abr 2001 1 Nov 2001 Curon Medical, Inc. Ablation of rectal and other internal body structures
WO2001080723A3 24 Abr 2001 4 Abr 2002 Curon Medical Inc Ablation of rectal and other internal body structures
WO2001082814B1 27 Abr 2001 2 May 2002 Bard Inc C R Apparatus and methods for mapping and ablation in electrophysiology procedures
WO2002005868A3 13 Jul 2001 9 Ene 2003 Transurgical Inc Thermal treatment methods and apparatus with focused energy application
WO2003007649A3 10 Jul 2002 11 Dic 2003 Transurgical Inc Ultrasonic transducers
WO2004023978B1 12 Sep 2003 19 Ago 2004 Prorhythm Inc Balloon alignment and collapsing system
WO2005009218A3 20 Jul 2004 9 Jun 2005 Biosense Webster Inc Ablation device with spiral array ultrasound transducer
WO2005032646A3 19 Jul 2004 20 Abr 2006 Eastern Virginia Med School Apparatus for generating electrical pulses and methods of using the same
WO2006022790A1 17 Nov 2004 2 Mar 2006 Ardian, Inc. Methods and devices for renal nerve blocking
WO2006041847A1 4 Oct 2005 20 Abr 2006 Ardian, Inc. Methods and apparatus for renal neuromodulation
WO2007035537A2 14 Sep 2006 29 Mar 2007 Ardian, Inc. Methods and apparatus for inducing controlled renal neuromodulation
WO2007078997A3 21 Dic 2006 23 Oct 2008 Ardian Inc Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
WO2007086965A2 26 Oct 2006 2 Ago 2007 Ardian, Inc. Methods and apparatus for intravascularly-induced neuromodulation
WO2007103879A2 5 Mar 2007 13 Sep 2007 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
WO2007103881A2 5 Mar 2007 13 Sep 2007 Ardian, Inc. Method and apparatus for neuromodulator! of renal neural fibers
WO2007121309A3 12 Abr 2007 20 Mar 2008 Ardian Inc Methods and apparatus for monopolar renal neuromodulation
WO2007124458A2 20 Abr 2007 1 Nov 2007 The Regents Of The University Of California Method of thermal treatment for myolysis and destruction of benign uterine tumors
WO2007146834A3 8 Jun 2007 28 Ago 2008 Ardian Inc Methods and apparatus for multi-vessel renal neuromodulation
WO2008052186A9 26 Oct 2007 28 Ago 2008 Ekos Corp Catheter with multiple ultrasound radiating members
WO2008061150A2 14 Nov 2007 22 May 2008 Ardian, Inc. Methods and apparatus for intravascularly-induced neuromodulation or denervation
WO2008070413A2 14 Nov 2007 12 Jun 2008 Ardian, Inc. Methods for treating heart arrhythmia
WO2009149315A2 5 Jun 2009 10 Dic 2009 Boston Scientific Scimed, Inc. Transducers, devices and systems containing the transducers, and methods of manufacture
WO2010033940A1 21 Sep 2009 25 Mar 2010 Minnow Medical, Inc Inducing desirable temperature effects on body tissue using alternate energy sources
WO2010078175A1 22 Dic 2009 8 Jul 2010 Ardian, Inc. Apparatus, systems and methods for achieving intravascular, thermally-induced renal neuromodulation
WO2011051872A2 25 Oct 2010 5 May 2011 Koninklijke Philips Electronics N.V. Radio frequency ablation catheter and magnetic resonance imaging system
WO2011053757A1 29 Oct 2010 5 May 2011 Sound Interventions, Inc. Method and apparatus for treatment of hypertension through percutaneous ultrasound renal denervation
WO2011053772A1 29 Oct 2010 5 May 2011 Sound Interventions, Inc. Method and apparatus for non-invasive treatment of hypertension through ultrasound renal denervation
WO2011059792A1 29 Oct 2010 19 May 2011 Sound Interventions, Inc. Method and apparatus for treatment of cardiac valve insufficiency
WO2011060200A1 11 Nov 2010 19 May 2011 Innovative Pulmonary Solutions, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
WO2011060201A1 11 Nov 2010 19 May 2011 Innovative Pulmonary Solutions, Inc. Methods and systems for screening subjects
WO2011080666A1 21 Dic 2010 7 Jul 2011 Koninklijke Philips Electronics N.V. Dynamic ablation device
WO2011088399A1 14 Ene 2011 21 Jul 2011 Stanford University Method and apparatus for radioablation of regular targets such as sympathetic nerves
WO2011094367A1 26 Ene 2011 4 Ago 2011 Evans Michael A Methods, devices, and agents for denervation
WO2012025245A1 26 Ago 2011 1 Mar 2012 Acandis Gmbh & Co. Kg Electrode for medical applications, system having such an electrode, and method for producing such an electrode
WO2012068354A2 17 Nov 2011 24 May 2012 Boston Scientific Scimed, Inc. Catheter guidance of external energy for renal denervation
WO2012112165A1 18 Feb 2011 23 Ago 2012 Recor Medical, Inc. Apparatus for effecting renal denervation using ultrasound
1 Arruda, M. S., et al. "Development and validation of an ECG algorithm for identifying aecessory pathway ablation site in Wolff-ParkinsonWhite syndrome." J Cardiovasc Electrophysiol, 9:2-12 (1998).
2 Avitall, B., et al. "The creation of linear continuous lesions in the atria with an expandable loop catheter." J Am Coll Cardiol, 33,4:972-984 (1999).
3 Bartlett, T. G., et al. "Current management of the Wolff-Parkinson-White syndrome." J Card Surg, 8:503-515 (1993).
4 Benito, F., et al. "Radio frequency catheter ablation of accessory pathways in infants," Heart, 78: 160-162 (1997).
5 Blumenfeld, J. D., et al. "alpha-Adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in norrnotensive and hypertensive subjects." AJH, 12:451-459 (1999).
6 Blumenfeld, J. D., et al. "α-Adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in norrnotensive and hypertensive subjects." AJH, 12:451-459 (1999).
7 Callans, D. J. "Narrowing of the superior vena cava-right atrium junction during radiofrequency catheter ablation for inappropriate sinus tachycardia: Analysis with intracardiac echocardiography." JACC, 33:1667-1670 (1999).
8 Callans, D. J. "Narrowing of the superior vena cava—right atrium junction during radiofrequency catheter ablation for inappropriate sinus tachycardia: Analysis with intracardiac echocardiography." JACC, 33:1667-1670 (1999).
9 Cao, H. et al. "Flow effect on lesion formation in RF cardiac catheter ablation." IEEE T Bio-Med Eng, 48:425-433 (2001).
10 Chen, S.-A., et al. "Complications of diagnostic electrophysiologic studies and radiofrequency catheter ablation in patients with tachyarrhythmias: An eight-year survey of 3,966 consecutive procedures in a tertiary referral center." Am J Cardiol, 77 :41-46 (1996).
11 Chen, Shih-Ann, M.D., "Initiation of Atrial Fibrillation by Ectopic Beats Originating From the Pulmonary Veins," Circulation 100(18):1879-86, 1999.
12 Chinitz, Larry A., "Mapping Reentry Around Atriotomy Scars Using Double Potentials," 1996.
13 Cioni, R., et al. "Renal artery stenting in patients with a solitary functioning kidney." Cardiovasc Intervent Radiol, 24:372-377 (2001).
14 Cosby, R. L., et al. "The role of the sympathetic nervous system and vasopressin in the pathogenesis of the abnormal sodium and water." Nefrologia, V, 4:271-277 (1985).
15 Cosio, Francisco G., "Atrial Flutter Mapping and Ablation II," Pacing & Clin. Electrophysiol. 19(6):965-75, 1996.
16 Cox J. L. et al. "Five-year experience with the Maze procedure for atrial fibrillation." Ann Thorac Surg, 56:814-824 (1993).
17 Cox, J. L. "The status of surgery for cardiac arrhythmias." Circulation, 71 :413-417 (1985).
18 Cruickshank, J. M. "Beta-blockers continue to surprise us." Eur Heart J, 21:354-364 (2000).
19 Curtis, J. J., et al. "Surgical therapy for persistent hypertension after renal transplantation," Transplantation, 31:125-128 (1981).
20 Demazumder, D., et al. "Comparison of irrigated electrode designs for radiofrequency ablation of myocardium." J Intent Card Electr, 5:391-400 (2001).
21 DiBona, G. F. "Neural control of the kidney: Functionally specific renal sympathetic nerve fibers." Am J Physiol Regulatory Integrative Comp Physiol, 279:R1517-R1524 (2000).
22 DiBona, G. F. "Sympathetic nervous system and kidney in hypertension," Nephrol and Hypertension, 11: 197-200 (2002).
23 DiBona, G. F., et al. "Neural control of renal function," Physiol Rev, 77:75-197 (1997).
24 DiBona, G. F., et al. "Renal hemodynamic effects of activation of specific renal sympathetic nerve fiber groups." Am J Physiol Regul lntegr Comp Physiol, 276:R539-R549 (1999).
25 Diederich, C. J. et al., Transurethral ultrasound array for prostate thermal therapy: initial studies, leee Transactions on Ultrasonics, Ferroelectrics and Frequency Control leee USA, vol. 43, No. 6, Nov. 1996, pp. 1011-1022, XP002717467, USA ISSN: 0885-3010.
26 Doggrell, S. A., et al. "Rat models of hypertension, cardiac hypertrophy and failure." Cardiovasc Res, 39:89-105 (1998).
27 Dong, Q., et al. "Diagnosis ofrenal vascular disease with MR angiography." RadioGraphies, 19:1535-1554 (1999).
28 Dubuc, M., et al. "Feasibility of cardiac cryoablation using a transvenous steerable electrode catheter," J Intent Cardiac Electrophysiol, 2:285-292 (1998).
29 Extended European Search Report, Application No. EP 10 72 9496, mailed Jul. 12, 2012.
30 Feld, Gregory K., "Radiofrequency Catheter Ablation for the Treatment of Human Type I Atrial Flutter," 1992.
31 Fjield, et al., U.S. Appl. No. 60/218,641, filed Jul. 13, 2000.
32 Gallagher, John J., "Wolff-Parkinson-White Syndrome: Surgery to Radiofrequency Catheter Ablation," 1997.
33 Gilard, M., et al. "Angiographic anatomy of the coronary sinus and its tributaries." PACE, 21:2280-2284 (1998).
34 Goriseh, W., et al. "Heat-indueed contraction of blood vessels." Lasers Surg Med, 2:1-13 (1982).
35 Haines, D. E., et al. "Tissue heating during radiofrequeney catheter ablation; a thermodynamic model and observations in isolated perfused and superfused canine right ventrieular free wall." PACE, 12:962-976 (1989).
36 Haissaguerre, Michel, "Electrophysiological End Point for Catheter Ablation of Atrial Fibrillation Initiated From Multiple Venous Foci," 1999.
37 Haissaguerre, Michel, M.D., "Predominant Origin of Atrial Panarrythmic Triggers in the Pulmonary Veins: A Distinct Electrophysiologic Entity," 1997.
38 Haissaguerre, Michel, M.D., "Radiofrequency Catheter Ablation in Unusual Mechanisms of Atrial Fibrillation," 1994.
39 Haissaguerre, Michel, M.D., "Right and Left Atrial Radiofrequency Catheter Therapy of Paroxysmal Atrial Fibrillation," 1996.
40 Haissaguerre, Michel, M.D., "Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins," 1998.
41 Han, Y-M. et al. "Renal artery embolization with diluted hot contrast medium: An experimental study," J Vasc Intent Radiol, 12:862-868 (2001).
42 Hansen, J. M., et al. "The transplanted human kidney does not achieve functional reinnervation." Clin Sci, 87, 1: 13-20 (1994).
43 Hatala, Robert, "Radiofrequency Catheter Ablation of Left Atrial Tachycardia Originating Within the Pulmonary Vein in a Patient with Dextrocardia," 1996.
44 Hindricks, G. "The Multicentre European Radiofrequency Survey (MERFS): Complications of radiofrequency catheter ablation of arrhythmias." Eur Heart J, 14:1644-1653 (1993).
45 Ho, S. Y., et al. "Architecture of the pulmonary veins: Relevance to radiofrequency ablation." Heart, 86:265-270 (2001).
46 Hocini, Meleze, "Concealed Left Pulmonary Vein Potentials Unmasked by Left Atrial Stimulation," 2000.
47 Hocini, Meleze, "Multiple Sources Initating Atrial Fibrillation from a Single Pulmonary Vein Identified by a Circumferential Catheter," 2000.
48 Hsieh, Ming-Hsiung, M.D., "Double Multielectrode Mapping Catheters Facilitate Radiofrequency Catheter Ablation of Focal Atrial Fibrillation Originating from Pulmonary Veins," 1998.
49 Huang et al., "Renal denervation prevents and reverses hyperinsulinemia-induced hypertension in rats," Hypertension 32, pp. 249-254 (1998).
50 Huang, S. K. S., et al. "Radiofrequency catheter ablation of cardiac arrhythmias: Basic concepts and clinical applications." 2nd ed. Armonk, NY: Futura Publishing Co. (2000).
51 Igawa, Osamu, "The Anatomical Features of the Junction between the Left Atrium and the Pulmonary Veins: the Relevance with Atrial Arrhythmia."
52 International Search Report for PCT/US2010/020333, mailed Feb. 25, 2010, 3 pages.
53 International Search Report, Application No. PCT/US01/22237.
54 International Search Report, Application No. PCT/US04/05197.
55 International Search Report, Application No. PCT/US07/11346.
56 International Search Report, Application No. PCT/US2001/022221.
57 Jackman, W. M., et al. "Treatment of supraventricular tachycardia due to atrioventricular nodal reentry by radiofrequency catheter ablation of slow-pathway conduction." N England J Med, 327, 5:313-318 (Jul. 30, 1992).
58 Jain, M. K., et al. "A three-dimensional finite element model of radiofrequency ablation with blood flow and its experimental validation." Ann Biomed Eng, 28:1075-1084 (2000).
59 Jais, Pierre, M.D., "A Focal Source of Atrial Fibrillation Treated by Discrete Radiofrequency Ablation," 1996.
60 Janssen, B. J. A., et al. "Renal nerves in hypertension." Miner Electrolyte Metab, 15:74-82 (1989).
61 Kapural, L., et al. "Radiofrequency ablation for chronic pain control." Curr Pain Headache Rep, 5:517-525 (2001).
62 Kay, G. Neal, "Radiofrequency Ablation for Treatment of Primary Atrial Tachycardia," 1993.
63 Koepke, J. P., et al. "The physiology teacher: Functions ofthe renal nerves." The Physiologist, 28, 1 :47-52 (1985).
64 Kompanowska, E., et al. "Early effects of renal denervation in the anaesthetised rat: Natriuresis and increased cortical blood flow," J Physiol, 531.2:527-534 (2001).
65 Krimholtz et al., "New Equivalent Circuits for Elementary Piezoelectric Transducers," Electronics Lettres, vol. 6, No. 13, pp. 398-399, Jun. 25, 1970.
66 Kumagai, Koichiro, "Treatment of Mixed Atrial Fibrillation and Typical Atrial Flutter by Hybrid Catheter Ablation," 2000.
67 Labonte, S. "Numerieal model for radio-frequency ablation of the endocardium and its experimental validation." IEEE T Bio-med Eng, 41,2:108-115 (1994).
68 Lee, S.-J., et al. "Ultrasonic energy in endoscopic surgery," Yonsei Med J, 40:545-549 (1999).
69 Leertouwer, T. c., et al. "In-vitro validation, with histology, of intravascular ultrasound in renal arteries." J Hypertens, 17:271-277 (1999).
70 Lesh, M.D., "An Anatomic Approach to Prevention of Atrial Fibrillation: Pulmonary Vein Isolation with Through-the-Balloon Ultrasound Ablation (TTB-US)," Thorac. Cardiovasc. Surg. 47 (1999) (Suppl.) 34751.
71 Lesh, M.D., "An Anatomic Approach to Prevention of Atrial Fibrillation: Pulmonary Vein Isolation with Through-the-Balloon Ultrasound Ablation (TTB-US)," Thorac. Cardiovasc. Surg. 47 (1999) (Suppl.) 347-51.
72 Lesh, Michael D., M.D., "Radiofrequency Catheter Ablation of Atrial Arrhythmias," 1994.
73 Liem, L. Bing, "In Vitro and In Vivo Results of Transcatheter Microwave Ablation Using Forward-Firing Tip Antenna Design," 1996.
74 Lin, Wei-Shiang, M.D., "Pulmonary Vein Morphology in Patients with Paroxysmal Atrial Fibrillation Initiated by Ectopic Beats Originating From the Pulmonary Veins," Circulation 101(11):1274-81, 2000.
75 Lowe, J. E. "Surgical treatment of the Wolff-Parkinson-White syndrome and other supraventricular tachyarrhythmias." J Card Surg, 1 :117-134 (1986).
76 Lundin, S. et al. "Renal sympathetic activity in spontaneously hypertensive rats and normotensive controls, as studied by three different methods." Acta Physiol Scand, 120,2:265-272 (1984).
77 Lustgarten, D. L., et al. "Cryothermal ablation: Mechanism of tissue injury and current experience in the treatment of tachyarrhythmias," Progr Cardiovasc Dis, 41:481-498 (1999).
78 Mallavarapu, Christopher, "Radiofrequency Catheter Ablation of Atrial Tachycardia with Unusual Left Atrial Sites of Origin," 1996.
79 McRury I. D., et al. "Nonunifonn heating during radiofrequency catheter ablation with long electrodes." Circulation, 96:4057-4064 (1997).
80 Mehdirad, A., et al. "Temperature controlled RF ablation in canine ventricle and coronary sinus using 7 Fr or 5 Fr ablation electrodes." PACE, 21:310-321 (1998).
81 Miller, B. F., and Keane, C. B. "Miller-Keane Encyclopedia & Dictionary 0/ Medicine, Nursing, & Allied Health." Philadelphia: Saunders (1997) ("ablation").
82 Misaki, T., et al. "Surgical treatment of patients with Wolff-ParkinsonWhite syndrome and associated Ebstein's anomaly." J Thorae Cardiovase Surg, 110: 1702-1707 (1995).
83 Moak, J. P., et al. "Case report: Pulmonary vein stenosis following RF ablation of paroxysmal atrial fibrillation: Successful treatment with balloon dilation." J Intery Card Electrophys, 4:621-631 (2000).
84 Montenero, Sandro, Annibale, "Electrograms for Identification of the Atrial Ablation Site During Catheter Ablation of Accessory Pathways," 1996.
85 Morrissey, D. M., "Sympathectomy in the treatment of hypertension."Lancet, CCLVIX:403-408 (1953).
86 Moubarak, Jean B., "Pulmonary Veins-Left Atrial Junction: Anatomic and Histological Study," Pacing & Clin. Electrophys. 23(11 pt. 2):1836-8, 2000.
87 Nakagawa, A., et al. "Selective ablation of porcine and rabbit liver tissue using radiofrequency: Preclinical study." Eur Surg Res, 31: 371-379 (1999).
88 Nakagawa, H., et al. "Comparison of in vivo tissue temperature profile and lesion geometry for radiofrequeney ablation with a saline-irrigated electrode versus temperature control in a eanine thigh muscle preparation." Circulation, 91 :2264-2273 (1995).
89 Nakagawa, H., et al. "Inverse relationship between electrode size and lesion size during radiofrequency ablation with active electrode cooling." Circulation, 98:458-465 (1998).
90 Neutel, J. M. "Hypertension and its management: A problem in need of new treatment strategies." JRAAS, I:S 1 O-S 13 (2000).
91 Nozawa, T., et al. "Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats." Heart Vessels, 16:51-56 (2002).
92 O'Connor, B. K., et al. "Radiofrequeney ablation of a posteroseptal accessory pathway via the middle cardiac vein in a six-year-old child." PACE, 20:2504-2507 (1997).
93 O'Connor, Brian K., "Radiofrequency Ablation of a Posteroseptal Accessory Pathway Via the Middle Cardia Vein in a Six-Year Old Child," 1997.
94 Oliveira et al., "Renal Denervation Normalizes Pressure and Baroreceptor Reflex in High Renin Hypertension in Conscious Rats," Hypertension Suppl. II vol. 19 No. 2, pp. 17-21 (1992).
95 Oral, H., et al. "Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation." Circulation, 105: 1077-1081 (2002).
96 Page, I., et al. "The effect of renal denervation on the level of arterial blood pressure and renal function in essential hypertension." J Clin Invest, XIV:27-30 (1935).
97 Panescu, D., et al. "Radiofrequency multielectrode catheter ablation in the atrium." Phys Med Biol, 44:899-915 (1999).
98 Partial European Search Report, Application No. 10 01 0582, Sep. 26, 2011.
99 Partial European Search Report, Application No. 10 01 0583, Sep. 28, 2011.
100 Partial Supplementary European Search Report, Application No. EP 01 95 2750, Filed Sep. 16, 2005.
101 Pavin, D., et al. "Permanent left atrial tachyeardia: Radiofrequency catheter ablation through the eoronary sinus." J Cardiovasc Electrophysiol, 12:395-398 (2002).
102 Peet, M., "Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy," Am. J. Surgery, pp. 48-68 (1948).
103 Petersen, H. H., et al. "Lesion dimensions during temperature controlled radiofrequency catheter ablation of left ventricular porcine myocardium: Impact of ablation site, electrode size, and convective cooling." Circulation, 99:319-325 (1999).
104 Pohl, M.A. "Renovaseular hypertension and isehemie nephropathy" A chapter in a book edited by Sehrier, R. W. "Atlas of diseases of the kidney: Hypertension and the kidney." Blackwell Science (1999).
105 Prager, Nelson, A., "Long Term Effectiveness of Surgical Treatment of Ectopic Atrial Tachycardia," 1993.
106 Pugsley, M. K., et al. "The vascular system: An overview of structure and function." J Pharmacol Toxical Methods, 44:333-340 (2000).
107 Rappaport et al., "Wide-Aperture Microwave Catheter-Based Cardiac Ablation", Proceedings of the First Joint BMES/EMBS Conference, Oct. 13-16, 1999, p. 314.
108 Response to Written Opinion under Article 34 for PCT/US2010/020333, filed Nov. 8, 2010, 13 pages.
109 Reuter, David, M.D., "Future Directions of Electrotherapy for Atrial Fibrillation," 1997.
110 Robbins, Ivan, M.D., "Pulmonary Vein Stenosis After Catheter Ablation of Atrial Fibrillation," 1998.
111 Sanderson, J. E. et al. "Effect of B-blockage on baroreceptor and autonomic function in heart failure." Clin Sei, 69:137-146 (1999).
112 Schauerte, P. et al. "Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation," Circulation, 102:2774-2780 (2000).
113 Scheinman, M. M., et al. "The 1998 NASPE prospective catheter ablation registry." PACE, 23:1020-1028 (2000).
114 Scheinman, Melvin M., "NASPE Survey on Catheter Ablation," 1995.
115 Smithwick et al., "Splanchnicectomy for Essential Hypertension," J. Am. Med. Assn. 152:16, pp. 1501-1504 (1953).
116 Solis-Herruzo et al., "Effects of Lumbar Sympathetic Block on Kidney Function in Cirrhotic Patients with Hepatorenal Syndrome," J. Hepatol. 5, pp. 167-173 (1987).
117 Stella A., et al. "Effects of reversible renal denervation on haemodynamic and excretory functions of the ipsilateral and contralateral kidney in the cat," J Hypertension, 4: 181-188 (1986).
118 Stellbrink, C., et al. "Transcoronary venous radiofrequency catheter ablation ofventricular tachyeardia." J Cardiovasc Electrophysiol, 8:916-921 (1997).
119 Supplementary European Search Report, Application No. EP 01 952 746.4, mailed Apr. 3, 2005.
120 Supplementary European Search Report, Application No. EP 01 952 750.6, mailed Dec. 13, 2005.
121 Supplementary European Search Report, Application No. EP 07 77 6968, mailed Feb. 1, 2010.
122 Swain, et al. Gastrointestial Endoscopy. 1994; 40:AB35.
123 Swartz, John F., "A Catheter-based Curative Approach to Atrial Fibrillation in Humans," 1994.
124 Swartz, John F., M.D., "Radiofrequency Endocardial Catheter Ablation of Accessory Atrioventricular Pathway Atrial Insertion Sites," 1993.
125 Takahashi, H., et al. "Retardation of the development of hypertension in DOCA-salt rats by renal denervation." Jpn Circ J, 48:567-574 (1984).
126 Tanaka et al., "A new radiofrequency thermal balloon catheter for pulmonary vein isolation," Journal of the American College of Cardiology 38(7): 2079-86, Dec. 2001.
127 Tracy, Cynthia M., "Radiofrequency Catheter Ablation of Ectopic Atrial Tachycardia Using Paced Activation Sequence Mapping," J. of the Amer. College of Cardiol. 21(4):910-7, 1993.
128 Tungjitkusolmun, S. "Ablation." A chapter in a book edited by Webster, J. G., "Minimally invasive medical technology." Bristol UK: IOP Publishing, 219 (2001).
129 U.S. Appl. No. 60/236,420, filed Sep. 28, 2000, Harrison et al.
130 U.S. Appl. No. 60/258,824, filed Nov. 6, 2009, Gelfand et al.
131 U.S. Appl. No. 60/370,190, filed Apr. 8, 2002, Levin et al.
132 U.S. Appl. No. 60/415,575, filed Oct. 3, 2002, Levin et al.
133 U.S. Appl. No. 60/442,970, filed Jan. 29, 2003, Gelfand et al.
134 Uchida, F., et al. "Effect of radio frequency catheter ablation on parasympathetic denervation: A comparison of three different ablation sites," PACE, 21:2517-2521 (1998).
135 Uflacker, R., "Atlas of vascular anatomy: An angiographic approach."Baltimore: Williams & Wilkins, 424 (1997).
136 Valente, J. F. "Laparoscopic renal denervation for intractable ADPKD-related pain," Nephrol Dial Transplant, 16:160 (2001).
137 Van Hare, G. F., et al. "Percutaneous radiofrequency catheter ablation for supraventricular arrhythmias in children." JACC, 17:1613-1620 (1991).
138 Van Hare, George F., "Radiofrequency Catheter Ablation of Supraventricular Arrhythmias in Patients With Congenital Heart Disease: Results and Technical Considerations," J. of the Amer. College of Cardiol. 22(3):883-90, 1993.
139 Volkmer, Marius, M.D., "Focal Atrial Tachycardia from Deep Inside the Pulmonary Veins," 1997.
140 Vujaskovie, Z., et al. "Effects of intraoperative hyperthermia on canine seiatie nerve: Histopathologie and morphometric studies." Int J Hyperthermia, 10,6:845-855 (1994).
141 Walsh, Edward P., M.D., "Transcatheter Ablation of Ectopic Atrial Tachycardia in Young Patients Using Radiofrequency Current," 1992.
142 Weinstock, M., et al. "Renal denervation prevents sodium retention and hypertension in salt-sensitive rabbits with genetic baroreflex impairment," Clinical Science, 90:287-293 (1996).
143 Weir, M. R., et al. "The renin-angiotensin-aldosterone system: A specific target for hypertension management." Am J Hypertens, 12:205S-213S (1999).
144 Written Opinion of the International Searching Authority for PCT/US2010/020333, mailed Feb. 25, 2010, 7 pages.
145 Yamamoto, T., et al. "Blood velocity profiles in the human renal artery by Doppler ultrasound and their relationship to atherosclerosis."Arterioscl Throm Vas, 16: 172-177 (1996).
146 Zhang et al., "The development of a RF electrical pole catheter for heart ablation," China Academic Journal Electronic Publishing House 23(5): 279-80, Sep. 1999.
147 Zipes, Douglas P., M.D., "Catheter Ablation of Arrhythmias," 1994.
Clasificación de EE.UU. 606/27, 601/3
Clasificación internacional A61B19/00, A61B17/22, A61B18/00, A61B18/04, A61N7/00, A61B17/00, A61N7/02
Clasificación cooperativa A61B2090/378, A61B2017/00703, A61B2018/00023, A61B2017/22051, A61N7/022, A61N2007/0078, A61B2017/00106, A61B2019/5276
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZOU, YONG;JUNG, EUGENE J.;WARNKING, REINHARD;AND OTHERS;SIGNING DATES FROM 20100126 TO 20100212;REEL/FRAME:023942/0785
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IYER, MANO;REEL/FRAME:024188/0738